Does Medicare Cover Zepbound?
Zepbound sits in unusual territory — approved for both weight loss and sleep apnea — and Medicare treats those two uses very differently.
It depends on why it's prescribed. Medicare Part D generally does not cover Zepbound (tirzepatide) for weight loss alone, because federal law excludes weight-loss drugs from Part D. But Zepbound also carries a separate FDA approval for moderate-to-severe obstructive sleep apnea in adults with obesity, and some plans cover it under that diagnosis. On top of that, a new temporary program starting July 1, 2026 — the Medicare GLP-1 Bridge — covers the Zepbound KwikPen specifically for weight loss at a $50 monthly copay through the end of 2027.
Zepbound is a genuinely more complicated case than most GLP-1 drugs because the FDA has approved it for two different things: chronic weight management, and moderate-to-severe obstructive sleep apnea (OSA) in people with obesity. Medicare's weight-loss drug exclusion only applies to the weight-loss use — so the sleep apnea approval opened a real, if narrow, coverage path that didn't exist before. Layer the brand-new 2026 Bridge program on top of that, and Zepbound now has more possible routes to coverage than almost any other drug in this category. Here's how each one actually works.
Why weight loss alone usually isn't covered
Since Medicare Part D's earliest formulary rules, drugs used for weight loss have been categorically excluded from coverage, regardless of how effective they are. That rule doesn't bend based on a patient's individual health risks from obesity — it's a blanket statutory exclusion tied to the drug's purpose, not the person taking it. Because Zepbound's primary, most prescribed use is weight management, a Part D plan generally cannot pay for it when that's the diagnosis on file, outside of the new Bridge program described below.
The sleep apnea pathway
In late 2024, the FDA expanded Zepbound's approval to include treatment of moderate-to-severe obstructive sleep apnea in adults who also have obesity. Because OSA is a distinct, diagnosable medical condition — not "weight loss" — this indication falls outside the weight-loss drug exclusion. That means a Part D or Medicare Advantage plan is legally permitted to cover Zepbound when it's prescribed for OSA, though whether it actually does depends on the plan's formulary decisions.
What's typically required
A documented diagnosis of moderate-to-severe obstructive sleep apnea, usually confirmed by a sleep study, plus obesity as a co-occurring condition.
Prior authorization
Most plans that cover Zepbound for OSA require prior authorization, with your doctor submitting the sleep study results and diagnosis codes.
Formulary variation
Not all Part D and Medicare Advantage plans include Zepbound on their formulary even for the OSA indication — this is a plan-by-plan decision.
Cost if approved
When covered for OSA, standard Part D cost-sharing applies: your deductible, copay tier, and coverage-gap rules, the same as any other covered brand-name drug.
The new Medicare GLP-1 Bridge program
Starting July 1, 2026, CMS is running a temporary demonstration called the Medicare GLP-1 Bridge, open to eligible members of participating Part D and MA-PD plans. It provides access to certain GLP-1 medications for weight loss — specifically Wegovy, Foundayo, and the Zepbound KwikPen — for a flat $50 copay per 30-day supply. The program runs through December 31, 2027, at which point CMS plans to transition to a longer-term replacement model.
Two details matter if you're considering this route for Zepbound. First, only the KwikPen formulation qualifies — the single-dose pen and vial versions of Zepbound are not included. Second, your specific Part D or MA-PD plan has to be participating in the Bridge, and you'll still need to meet the program's prior authorization and eligibility criteria, which are built around weight and obesity-related health criteria rather than a blanket "anyone who wants it" approval.
How to check your specific plan
Given how many variables are in play — indication, formulary, prior authorization, and now a temporary demonstration program — the only reliable way to know your actual coverage is to check directly. Search your plan's formulary for "tirzepatide" or "Zepbound," and when you call member services, ask specifically: is Zepbound covered under my plan, for which diagnosis, does it require prior authorization, and does my plan participate in the Medicare GLP-1 Bridge for 2026. If you're prescribed Zepbound for sleep apnea, ask your doctor's office to include your sleep study documentation with any prior authorization request, since that's typically the deciding factor.
Frequently Asked Questions
Does Medicare cover Zepbound for weight loss?
Not through standard Part D coverage — federal law excludes weight-loss drugs from Part D formularies. But starting July 1, 2026, the temporary Medicare GLP-1 Bridge program covers the Zepbound KwikPen for weight loss at a $50 monthly copay for eligible members whose plan participates, through December 31, 2027.
Does Medicare cover Zepbound for sleep apnea?
It can. Zepbound is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity, which is a distinct medical condition, not just weight loss. Some Part D plans cover it for this indication if it's on their formulary and prior authorization confirming an OSA diagnosis is approved.
What's the difference between Zepbound and Mounjaro?
Both contain the same active ingredient, tirzepatide, from the same manufacturer, but under different FDA-approved uses. Mounjaro is approved for type 2 diabetes and is typically covered by Part D like other diabetes drugs. Zepbound is approved for weight management and sleep apnea, which subjects it to the weight-loss drug exclusion unless the sleep apnea indication or the Bridge program applies.
Which Zepbound formulation is covered under the GLP-1 Bridge?
Only the Zepbound KwikPen. The single-dose pen and vial formulations are not included in the Bridge program as of 2026.
How do I find out if my plan covers Zepbound?
Check your Part D or Medicare Advantage plan's formulary for tirzepatide or Zepbound, or call member services and ask whether it's covered, under what diagnosis, what tier it's on, and whether your plan participates in the GLP-1 Bridge program.
This article is for general educational purposes and reflects Medicare rules as of August 2026. It is not medical or insurance advice. Coverage depends on your individual diagnosis, prescription, and plan — confirm specifics with your doctor and your Medicare Part D or Medicare Advantage plan.